MentionFox
Home › Executive changes › Iovance Biotherapeutics, Inc.
Leadership changes · IOVA · SEC Form 8-K, Item 5.02

Leadership changes at Iovance Biotherapeutics, Inc. (2026)

Before you join, sell to or invest in Iovance Biotherapeutics, Inc.

MentionFox check on Iovance Biotherapeutics, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/iovance-biotherapeutics

Check Iovance Biotherapeutics, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Iovance Biotherapeutics, Inc.?

Who joined and who left Iovance Biotherapeutics, Inc. (IOVA)? 1 departure reported on 2026-03-20, each cited to the company's own filing.

Wendy Yarno left the role of Director at Iovance Biotherapeutics, Inc. As of November 14, 2026, Iovance Biotherapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 20, 2026, naming 1 departure (Form 8-K, March 20, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

STATE STREET CORPORATION also filed stake reports on 378 other companies ↓

Sell to companies like Iovance Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Out (departing)1
Latest filing2026-03-20

Iovance Biotherapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-20. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Iovance Biotherapeutics, Inc. files it.

Also on the record for Iovance Biotherapeutics, Inc.

DateRecordFigureOur pageSource
November 10, 2026Stake report, Schedule 13G, by STATE STREET CORPORATION4.8% of the class5%+ stakesSource
August 7, 2026Stake report, Schedule 13G, by STATE STREET CORPORATION5.5% of the class5%+ stakesSource
July 28, 2026Stake report, Schedule 13G/A, by BlackRock, Inc.7.5% of the class5%+ stakesSource
May 12, 2026Stake report, Schedule 13G, by STATE STREET CORPORATION4.2% of the class5%+ stakesSource
March 27, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource
February 9, 2026Stake report, Schedule 13G, by STATE STREET CORPORATION5.1% of the class5%+ stakesSource
July 29, 2025Stake report, Schedule 13G/A, by The Vanguard Group7.5% of the class5%+ stakesSource
July 17, 2025Stake report, Schedule 13G/A, by BlackRock, Inc.6.4% of the class5%+ stakesSource

Selling to them or working with them? See who runs Iovance Biotherapeutics, Inc. now and the warning signs.

Watch Iovance Biotherapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Iovance Biotherapeutics, Inc. and the records around it.

Iovance Biotherapeutics, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Iovance Biotherapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Iovance Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Iovance Biotherapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    9 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-03-20OutDirector8-K, 2026-03-20

Why did they leave? What the filings say

For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.

Who leads Iovance Biotherapeutics, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Iovance Biotherapeutics, Inc.?

New leaders reset buying decisions — get the Full Report on Iovance Biotherapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Iovance Biotherapeutics, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Director at Iovance Biotherapeutics, Inc., with the record behind each one.

Find candidates like Director at Iovance Biotherapeutics, Inc.

Every change, in the filing's words

Filed 2026-03-20 · 8-K

Departing: Wendy Yarno, Director

On March 17, 2026, Wendy Yarno, a member of the Board of Directors (the " Board ") of Iovance Biotherapeutics, Inc. (the " Company "), provided notice to the Board that she will retire from the Board and not be standing for re-election at the Company's annual meeting of stockholders (the " Annual Meeting ") currently anticipated to be held in June 2026.

Also stated in this filing

  • Ms. Yarno will serve out her current term as a director of the Company until the Annual Meeting.
  • The Company thanks Ms. Yarno for her service to the Board.

Tools for this story

Each opens in a new tab, filled in for Iovance Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/iovance-biotherapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Iovance Biotherapeutics, Inc. executive departure 2026. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/iovance-biotherapeutics